F. Ou

A. Oberg, S. Michiels, Y. Shyr, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Donna Niedzwiecki, Federico Innocenti, Fang-Shu Ou, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper

O. W. Lindwasser, J. Zell, M. Diehn, 2020, Nature Reviews Clinical Oncology.

The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

S. Alberts, S. Lazzi, F. Ou, 2020, Translational oncology.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Afsaneh Barzi, Katrina Pedersen, Jeannine S McCune, 2019, The Lancet. Oncology.

PULSE: A randomized phase II open label study of panitumumab rechallenge versus standard therapy after progression on anti-EGFR therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).

H. Lenz, J. Larson, A. Cercek, 2021 .

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial.

J. Meyerhardt, E. Giovannucci, S. Ogino, 2019, European journal of cancer.

Marine omega‐3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance)

J. Meyerhardt, E. Giovannucci, S. Alberts, 2019, International journal of cancer.

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

R. Labianca, E. Oki, T. Yamanaka, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405

J. Meyerhardt, A. Benson, C. Fuchs, 2020, JNCI cancer spectrum.

Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance)

Sushant A. Patil, Y. Furukawa, K. Owzar, 2020, Clinical Cancer Research.

FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience

G. Gores, M. Borad, L. Roberts, 2021, JCO precision oncology.

Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.

J. Meyerhardt, C. Fuchs, R. Goldberg, 2020, JAMA oncology.

Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer

H. Lenz, H. Hurwitz, M. Fakih, 2022, JAMA network open.

Modeling tumor measurement data to predict overall survival (OS) in cancer clinical trials

S. Mandrekar, F. Ou, Ming-Wen An, 2021, Contemporary clinical trials communications.

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer

G. Ha, S. Balk, F. Ou, 2021, Cancers.

Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials

D. Sargent, S. Mandrekar, A. Grothey, 2019, Contemporary clinical trials communications.

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial

D. Sahani, J. Meyerhardt, Douglas B. Evans, 2019, Annals of Surgical Oncology.

Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas

L. Schwartz, J. Meyerhardt, E. Collisson, 2017, BMC Cancer.

Incidence and Prognostic Significance of Thrombocytopenia Developed During Acute Coronary Syndrome in Contemporary Clinical Practice

W. Gibler, E. Ohman, E. Peterson, 2009, Circulation.

Hospital performance and differences by kidney function in the use of recommended therapies after non-ST-elevation acute coronary syndromes.

W. Gibler, E. Ohman, E. Peterson, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Pay for performance, quality of care, and outcomes in acute myocardial infarction.

Fang-Shu Ou, Elizabeth R DeLong, John S Rumsfeld, 2007, JAMA.

Troponin-positive, MB-negative patients with non-ST-elevation myocardial infarction: An undertreated but high-risk patient group: Results from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network-Get With The Guidelines (NCDR ACTION-GWTG) Registry.

L. Newby, J. D. de Lemos, M. Roe, 2010, American heart journal.

Care Processes Associated With Quicker Door-In–Door-Out Times for Patients With ST-Elevation–Myocardial Infarction Requiring Transfer: Results From a Statewide Regionalization Program

Sean M. O'Brien, C. Cairns, C. Granger, 2011, Circulation. Cardiovascular quality and outcomes.

Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.

E. Kimby, E. Hoster, A. Hagenbeek, 2021, Blood advances.

Nationally representative equations that include resistance and reactance for the prediction of percent body fat in Americans

S. Heymsfield, J. Stevens, Jianwen Cai, 2017, International Journal of Obesity.

Clinical significance of post-procedural TIMI flow in patients with cardiogenic shock undergoing primary percutaneous coronary intervention.

J. Rumsfeld, E. Peterson, M. Roe, 2009, JACC. Cardiovascular interventions.

Weight‐Based Dosing of Enoxaparin in Obese Patients with Non‐ST‐Segment Elevation Acute Coronary Syndromes: Results from the CRUSADE Initiative

K. Alexander, W. Gibler, E. Ohman, 2009, Pharmacotherapy.

Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR).

J. Rumsfeld, E. Peterson, L. Klein, 2009, Journal of the American College of Cardiology.

Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Associati

E. Peterson, S. Bangalore, F. Messerli, 2009, American heart journal.

Trends in the Association Between Age and In-Hospital Mortality After Percutaneous Coronary Intervention: National Cardiovascular Data Registry Experience

J. Spertus, J. Rumsfeld, E. Peterson, 2009, Circulation. Cardiovascular interventions.

Registry Development of a Clinical Risk Algorithm From the National Cardiovascular Data Bleeding in Patients Undergoing Percutaneous Coronary Intervention :

J. Spertus, E. Peterson, M. Roe, 2009 .

Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)

J. Meyerhardt, C. Fuchs, R. Goldberg, 2019, JNCI cancer spectrum.

Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome.

K. Alexander, E. Peterson, J. Stafford, 2011, American heart journal.

Changes in beliefs about medications during long-term care for ischemic heart disease.

K. Alexander, E. Peterson, J. Stafford, 2010, American heart journal.

Secondary Prevention After Coronary Artery Bypass Graft Surgery: Findings of a National Randomized Controlled Trial and Sustained Society-Led Incorporation Into Practice

E. DeLong, E. Peterson, T. Ferguson, 2011, Circulation.

Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer

P. Stafford, R. Goldberg, H. Lenz, 2021, Oncogene.

Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative.

L. Newby, W. Gibler, E. Ohman, 2009, American heart journal.

An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence.

C. Cairns, W. Gibler, E. Ohman, 2009, Annals of Emergency Medicine.

Impact of a Statewide ST-Segment–Elevation Myocardial Infarction Regionalization Program on Treatment Times for Women, Minorities, and the Elderly

Sean M. O'Brien, Greg Mears, Charles B Cairns, 2010, Circulation. Cardiovascular quality and outcomes.

Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry.

Fang-Shu Ou, John S Rumsfeld, J. Rumsfeld, 2008, JACC. Cardiovascular interventions.

Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome.

K. Alexander, L. Newby, J. Rumsfeld, 2009, The American journal of cardiology.

Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance)

C. Gross, J. Meyerhardt, A. Benson, 2021, JNCI cancer spectrum.

Patient- and trial-specific barriers to participation in cardiovascular randomized clinical trials.

G. Felker, L. Newby, S. Martin, 2013, Journal of the American College of Cardiology.

Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes.

K. Alexander, L. Newby, W. Gibler, 2008, European heart journal.

Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)

M. Bertagnolli, G. Meijer, B. Carvalho, 2022, Epigenetics.

Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes.

Deepak L. Bhatt, C. Cannon, W. Gibler, 2009, European heart journal.

Prediction of percent body fat measurements in Americans 8 years and older

S. Heymsfield, J. Cai, J. Stevens, 2016, International Journal of Obesity.

BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study

A. Grothey, H. Hurwitz, M. Fakih, 2019, Annals of Oncology.

Randomized Phase II Study of PET Response–Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Kisha Mitchell, J. Meyerhardt, W. Frankel, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

J. Meyerhardt, C. Fuchs, R. Goldberg, 2020, JNCI cancer spectrum.

Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405.

J. Meyerhardt, K. Van Loon, C. Fuchs, 2021, Journal of the National Cancer Institute.

Racial differences in survival and response to therapy in patients with metastatic colorectal cancer: A secondary analysis of CALGB/SWOG 80405 (Alliance A151931)

H. Lenz, A. Venook, F. Innocenti, 2021, Cancer.

Abstract LB-235: COLOMATE: Colorectal cancer and liquid biopsy screening protocol for molecularly assigned therapy

T. Bekaii-Saab, S. Kopetz, T. Zemla, 2019, Clinical research.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

J. Meyerhardt, C. Fuchs, R. Goldberg, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.

Qian Shi, Daniel J. Sargent, Fang-Shu Ou, 2017 .

Combined impact of age and estimated glomerular filtration rate on in-hospital mortality after percutaneous coronary intervention for acute myocardial infarction (from the American College of Cardiology National Cardiovascular Data Registry).

Emir Veledar, Fang-Shu Ou, Leslee J Shaw, 2009, The American journal of cardiology.

Age and Persistent Use of Cardiovascular Medication After Acute Coronary Syndrome: Results from Medication Applied and Sustained Over Time

Chiara Melloni, Fang-Shu Ou, K. Alexander, 2009, Journal of the American Geriatrics Society.

Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance).

J. Meyerhardt, A. Venook, H. Kennecke, 2022, Endocrine-related cancer.

Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance)

D. Spiegelman, C. Gross, J. Meyerhardt, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial

J. Meyerhardt, E. Giovannucci, C. Atreya, 2020, JAMA network open.

Guidelines for Statistical Reporting in Medical Journals.

S. Mandrekar, K. Ballman, A. Adjei, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Changes in Prescribing Patterns in Stage III Colon Cancer.

J. Larson, T. Bekaii-Saab, F. Ou, 2023, Journal of the National Comprehensive Cancer Network : JNCCN.

Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer

J. Meyerhardt, A. Benson, E. Giovannucci, 2022, JAMA network open.

A prospective genome-wide study of prostate cancer metastases reveals association of wnt pathway activation and increased cell cycle proliferation with primary resistance to abiraterone acetate–prednisone

Krishna R. Kalari, Liang Wang, K. Kalari, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

E. Van Cutsem, A. Grothey, F. Kabbinavar, 2023, Cancers.

Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool.

Sunil V. Rao, E. Peterson, K. Shunk, 2011, JACC: Cardiovascular Interventions.

Survival of patients undergoing rescue percutaneous coronary intervention: development and validation of a predictive tool.

E. Peterson, K. Shunk, M. Roe, 2011, JACC. Cardiovascular interventions.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies.

S. Mandrekar, A. Ruppert, F. Ou, 2019, JCO precision oncology.

Influence of genetic variation in the vitamin D pathway on plasma 25-hydroxyvitamin D3 levels and survival among patients with metastatic colorectal cancer

J. Meyerhardt, H. McLeod, C. Fuchs, 2019, Cancer Causes & Control.

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).

M. Ziepert, N. Schmitz, C. Flowers, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors associated with off-label use of drug-eluting stents in patients with ST-elevation myocardial infarction.

B. Gersh, J. Spertus, J. Rumsfeld, 2008, The American journal of cardiology.

Percutaneous coronary interventions in facilities without cardiac surgery on site: a report from the National Cardiovascular Data Registry (NCDR).

R. Brindis, Mandeep Singh, F. Ou, 2009, Journal of the American College of Cardiology.

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.

A. Venook, J. Millstein, F. Ou, 2024, European Journal of Cancer.

CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value

Taline Khoukaz, A. Venook, J. Millstein, 2024, Journal for immunotherapy of cancer.

DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.

N. Rashid, A. Venook, F. Ou, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Milestone prediction for time‐to‐event endpoint monitoring in clinical trials

Martin Heller, Qian Shi, Fang-Shu Ou, 2019, Pharmaceutical statistics.

A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations.

T. Bekaii-Saab, F. Ou, K. Ciombor, 2023, Journal of Clinical Oncology.

Potential unintended financial consequences of pay-for-performance on the quality of care for minority patients.

E. Peterson, F. Ou, B. Lytle, 2008, American heart journal.

Using multistate models with clinical trial data for a deeper understanding of complex disease processes.

F. Ou, Terry M Therneau, 2024, Clinical trials.